FDA Advisory Panel Backs Moderna’s mRNA Flu Vaccine For Older Adults

A panel of U.S. regulators has thrown its support behind Moderna’s experimental mRNA-based flu vaccine, clearing a major hurdle toward potential use in older adults ahead of the upcoming influenza season.

The Food and Drug Administration’s advisory committee voted unanimously that the benefits of the shot, called mFluSVA, outweigh its risks for people aged 50 and older.

FDA Moves Closer To Approval

The FDA is now reviewing the recommendation as it considers full approval for adults aged 50 to 64, along with an additional authorization for those aged 65 and older. A final regulatory decision is expected by early August, in time to influence this year’s vaccination campaigns.

Each year, influenza kills tens of thousands of Americans and hospitalizes many more, with older adults facing the highest rates of severe illness and death. Existing vaccines, including high-dose and enhanced formulations, are specifically recommended for people aged 65 and above.

However, traditional flu vaccines require months of preparation and are based on viral strains selected well before the season begins. Because influenza viruses mutate rapidly, this can result in mismatches that significantly reduce vaccine effectiveness.

mRNA Technology Enters The Flu Vaccine Market

Moderna’s new vaccine uses the same messenger RNA platform that proved highly effective during the COVID-19 pandemic. With mRNA technology, manufacturers can update and produce vaccines much more quickly than with conventional egg-based or cell-based methods.

Experts on the FDA advisory panel said this speed could be particularly valuable if dominant flu strains shift unexpectedly, allowing public health authorities to respond more rapidly. They argued that adding an mRNA option expands the available tools for addressing both seasonal influenza and future pandemic threats.

Panel member Dr. Flor Munoz-Rivas of Texas Children’s Hospital said the technology could strengthen preparedness for emerging variants. Other advisers highlighted the potential for more accurate strain matching from year to year, although current vaccine policies still require strain selection well in advance.

Clinical Trial Results And Safety Findings

Moderna presented data from a clinical trial involving approximately 40,000 adults aged 50 and older. In this study, the mRNA vaccine reduced symptomatic influenza cases by roughly 27 percent compared with a widely used conventional flu vaccine.

In a smaller study involving adults aged 65 and older, mFluSVA generated stronger immune responses than an existing high-dose vaccine commonly recommended for seniors. Panel members described these immune markers as encouraging and consistent with strong protection against circulating flu strains.

Safety data revealed no major concerns, although local and systemic side effects such as injection-site pain, fatigue, fever, headache, and muscle aches occurred more frequently than with traditional flu vaccines. Regulators noted that this pattern resembles what has been observed with COVID-19 mRNA vaccines.

Advisers emphasized that these short-lived reactions often indicate a robust immune response, but they also called for clear communication so older adults understand what to expect. The FDA added that more data are still needed for frail seniors and individuals with weakened immune systems.

What Happens Next

If the FDA grants approval, Moderna plans to launch a large post-marketing study involving 400,000 adults aged 65 and older across two influenza seasons. Half of the participants would receive the mRNA vaccine, while the other half would receive a currently recommended senior-targeted flu vaccine, allowing researchers to compare real-world effectiveness and safety.

The company is also expanding research into younger age groups and plans to begin a dedicated study in adolescents aged 9 to 17 later this year. Positive results could support broader approval in future seasons.

Experts say mRNA flu vaccines could eventually allow more flexible timelines for selecting viral strains, similar to the annual update process used for COVID-19 boosters. For now, the key question is whether regulators move quickly enough for mFluSVA to be available alongside traditional flu vaccines this winter.

Regardless of the final decision, the advisory panel’s endorsement marks an important step in the evolution of influenza prevention. If approved, Moderna’s vaccine would become the first mRNA-based flu vaccine available in the United States, potentially reshaping seasonal flu protection for millions of older adults.